{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:25:27Z","timestamp":1793298327716,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100015797","name":"\u00d6sterreichische Kardiologische Gesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003100","name":"F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003100","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006212","name":"Hellenic Cardiological Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019191","name":"Sociedade Portuguesa de Cardiologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.amjmed.2014.05.003","type":"journal-article","created":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T15:15:50Z","timestamp":1399994150000},"page":"979-986.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The\u00a0Euro Heart Survey"],"prefix":"10.1016","volume":"127","author":[{"given":"Maura","family":"Marcucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robby","family":"Nieuwlaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Pisters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry J.G.M.","family":"Crijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2014.05.003_bib1","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2014.05.003_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2014.05.003_bib3","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2014.05.003_bib4","first-page":"125","article-title":"Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate\/rhythm control","volume":"28","author":"Skanes","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.amjmed.2014.05.003_bib5","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2014.05.003_bib6","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1160\/TH12-03-0175","article-title":"The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study","volume":"107","author":"Olesen","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2014.05.003_bib7","first-page":"190","article-title":"Guideline: The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation","volume":"29","author":"Ogawa","year":"2013","journal-title":"J\u00a0Arrhythmia"},{"key":"10.1016\/j.amjmed.2014.05.003_bib8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for\u00a0predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRatrial fibrillation)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2014.05.003_bib9","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1378\/chest.130.5.1390","article-title":"Development of a contemporary bleeding risk model for elderly warfarin recipients","volume":"130","author":"Shireman","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2014.05.003_bib10","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2014.05.003_bib11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A\u00a0new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2014.05.003_bib12","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1538-7836.2011.04378.x","article-title":"Bleeding risk in \u2018real world\u2019 patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort","volume":"9","author":"Olesen","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.amjmed.2014.05.003_bib13","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1378\/chest.10-3024","article-title":"Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation","volume":"140","author":"Poli","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2014.05.003_bib14","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2014.05.003_bib15","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2013.08.1623","article-title":"The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial Fibrillation","volume":"62","author":"Rold\u00e1n","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2014.05.003_bib16","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1160\/TH13-07-0552","article-title":"Comparison of the CHADS2, CHA2DS2 -VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial","volume":"110","author":"Apostolakis","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2014.05.003_bib17","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2014.05.003_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"Lip","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2014.05.003_bib19","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(12)60986-6","article-title":"Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial","volume":"380","author":"Lopes","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2014.05.003_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0197-2456(96)00092-X","article-title":"Benefit-risk ratios in the assessment of the clinical evidence of a new therapy","volume":"18","author":"Willan","year":"1997","journal-title":"Control Clin Trials"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934314003878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934314003878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:28:01Z","timestamp":1762079281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934314003878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0002934314003878"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2014.05.003","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The\u00a0Euro Heart Survey","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2014.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}